DBBHL agresif lenfomalar içinde yer alır ve en sık görülen lenfoma tipidir (%30). Germinal merkez... more DBBHL agresif lenfomalar içinde yer alır ve en sık görülen lenfoma tipidir (%30). Germinal merkezde lenfosit proliferasyonu ve dengesi apoptosis ile olmaktadır. Apoptosis ise iki yolun ortak çalısması ile düzenlenir. Bu yollardan biri hücre dısı yol digeri ise hücre içi yoldur. Hücre dısı yol çogunlukla TNF ailesi üyeleri arasında TRAIL, reseptörleri ve Fas/Fas-L üzerinden gerçeklesir. Bu ligand ve reseptör etkilesmesi sonucu hücre içi ölüm domaini (death domain; DD) aktive olur ve kaspazları aktiflestirirler. Kaspaz aktivasyonu ise apoptosis ile sonuçlanır. Bu çalısmada amacımız lenfoma patogenezinde rol oynayan reseptör ve ligandların klinik verilerle iliskisini saptamaktır. lk defa bu çalısmada literatürde daha önce yapılmamıs olan DBBHL’lı hastalarda TRAIL, TRAIL-DR4 ve TRAIL-DR5 düzeylerinin Fas/Fas-L sistemi ile birlikte tedavi öncesi ve sonrası düzeyleri ile diger klinik parametrelerin karsılastırması yapıldı. Çalısmaya Ocak 2005 ve Ekim 2007 arası DBBHL tanılı toplam 4...
e19107 Background: In this study, the efficacy and safety of pemetrexed chemotherapy was evaluate... more e19107 Background: In this study, the efficacy and safety of pemetrexed chemotherapy was evaluated retrospectively in patients who were non-responders to or who have demonstrated progression after the first and/or second line treatments in local advanced and metastatic NSCLC. Methods: 175 patients (139 males, 36 females) were assessed in years 2008 – 2012. Patients were given pemetrexed 500 mg/m2, and the ones receiving combined treatment were given pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 once in every 21 days. Supplementary steroid and vitamin treatment were administered to all patients. Age, gender, performance status (PS), stage, single agent or combined administration of treatment, progression-free survival (PFS) and overall (OS) were investigated. Patients were assessed in terms of treatment efficacy and toxicity. Results: Median follow-up period was 6 months (1 - 25), and median age was 55 years (28 - 83). In 82% of patients, PS was 0 – 1. 73% of patients were at stage 4. ...
e14705 Background: The addition of bevacizumab to chemotherapy significantly shows survival advan... more e14705 Background: The addition of bevacizumab to chemotherapy significantly shows survival advantage in metastatic colorectal cancer (mCRC), but with limited data about irinotecan combination in salvage therapy. Efficacy and toxicity of bevacizumab combination regimens were assessed in first-line and salvage therapies. Methods: Total of 1011 (659 in first-line and 352 in salvage) patients were retrospectively evaluated. Results: In first-line therapy, the ORR was 36.4%. Median PFS was 7 months for FOLFIRI, 6 months for IFL and 6 months for other chemotherapy regimens with a median overall PFS of 7 months. Median survival was 29 months for FOLFIRI, 28 months for IFL and 21 months for others with a median overall survival of 28 months. In salvage therapy, the ORR was 25.2%. Median PFS was 7 months for FOLFIRI, 7 months for IFL and 6 months for others with a median overall PFS of 7 months. Median survival was 19 months for FOLFIRI, 13 months for IFL and 21 months for others with a med...
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
Small bowel adenocarcinoma (SBA) is a rare tumor of the gastrointestinal system with poor prognos... more Small bowel adenocarcinoma (SBA) is a rare tumor of the gastrointestinal system with poor prognosis. Since these are rarely encountered tumors, there are limited numbers of studies investigating systemic treatment in advanced SBA. The purpose of this study was to evaluate the prognostic factors and systemic treatments in patients with advance SBA. Seventy-one patients from 18 Centers with advanced SBA were included in the study. Fifty-six patients received one of the four different chemotherapy regimens as first-line therapy and 15 patients were treated with best supportive care (BSC). Of the 71 patients, 42 (59%) were male and 29 (41%) female with a median age of 56 years. Median follow- up duration was 14.3 months. The median progression free survival (PFS) and overall survival (OS) were 7 and 13 months, respectively (N=71). In patients treated with FOLFOX (N=18), FOLFIRI (N=11), cisplatin-5-fluorouracil/ 5-FU (N=17) and gemcitabine alone (N=10), median PFS was 7, 8, 8 and 5 month...
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
To investigate the relationship between hepatic steatosis (HS) (at the time of diagnosis) and hep... more To investigate the relationship between hepatic steatosis (HS) (at the time of diagnosis) and hepatic metastasis (at the time of diagnosis and follow-up) in metastatic breast cancer (BC) patients by using computed tomography (CT). A total of 107 metastatic BC patients who had an abdominal CT were retrospectively enrolled in this study. Patients without HS (N=79) were regarded as the control group and those with HS constituted the HS study group (N-28). Hepatic metastases at diagnosis and during follow-up were more common in patients with HS (p=0.018 and p=0.041, respectively) and in the premenopausal group (p<0.001 and p=0.004, respectively), whereas they were similar in patients with and without HS in the postmenopausal group (p=0.655 and p=0.656, respectively). Overall survival rates were similar in patients with and without HS (p=0.606). Hepatic metastases at diagnosis and during follow-up were more frequent in patients with HS, especially in premenopausal patients. Survival w...
Asian Pacific journal of cancer prevention : APJCP, 2014
To investigate clinicopathological features in patients with recurrent colorectal cancer within 1... more To investigate clinicopathological features in patients with recurrent colorectal cancer within 1 year and more than 1 year after curative resection. We retrospectively evaluated 103 patients with disease recurrence before versus after 1 year of resection. Thirty-two patients (31%) were diagnosed with recurrence less than 1 year after curative resection for colorectal cancer (early recurrence) and 71 (69%) after more than 1 year (non-early recurrence). The early recurrence group displayed a significantly lower overall survival rate for both colon cancer (p=0, 01) and rectal cancer (p<0.001). Inadequate lymph node dissection was a significant predictor for early relapse. There were no statistically significant differences in clinicopathological variables such as age, sex, primary tumor localization, stage, depth of invasion, lymphovascular invasion and perineural invasion between the early and non-early recurrence groups. However, a K-ras mutation subgroup was significantly associ...
e20603 Background: β-glucans have antibacterial, immunomodulator and anti-cancer effects. The pre... more e20603 Background: β-glucans have antibacterial, immunomodulator and anti-cancer effects. The present study aimed to determine the effect of oral β-glucan on mucositis and leukopenia in a group of colorectal cancer patients with a high risk for neutropenia and mucositis who received adjuvant FOLFOX-4 (oxaliplatin, 5-flourouracil, and folinic acid) combination chemotherapy. Methods: This retrospective study included 62 patients with colorectal cancer that underwent a FOLFOX-4 treatment regimen between July 2009 and July 2010. Ethics committee of Erciyes University approved the study design. Colorectal cancer patients treated with a FOLFOX-4 regimen were retrospectively evaluated in 2 equal groups: One group received β-glucan (treatment group), and the other did not (control group). In both groups the level of leucocytes, neutrophils, and platelets were evaluated before and 1 week after chemotherapy. The occurrence of oral mucositis and diarrhea was noted. Data were statistically anal...
e14672 Background: There is no suggested molecular indicator in identifying which patients will b... more e14672 Background: There is no suggested molecular indicator in identifying which patients will benefit from anti-angiogenic treatment in metastatic colorectal cancer. Over expression of vascular endothelial growth factor (VEGF) and Hypoxia Inducible Factor 1-alpha (HIF-1α) are associated with bad prognosis. In this study, VEGF and HIF-1α expression and their clinical significance are studied in tumor tissues of patients with colorectal cancer receiving treatment with bevacizumab. Methods: VEGF and HIF-1α were observed immunohistochemically in primary tumors of 53 patients. The expressions were separated by evaluating low and high of VEGF and HIF-1α expression. We evaluated whether expression of VEGF and HIF-1α can help to predict treatment response, progression free survival (PFS), and overall survival (OS). Results: Fifty-three patients were enrolled in the study. Median age was 55. VEGF was strongly expressed in 30 patients (57%) whilst low expression was observed in 23 of them (...
Surgery is the only curative treatment for operable non-small lung cancer (NSCLC) and the importa... more Surgery is the only curative treatment for operable non-small lung cancer (NSCLC) and the importance of adjuvant chemotherapy for stage IB patients is unclear. Herein, we evaluated prognostic factors for survival and factors related with adjuvant treatment decisions for stage I and IIA NSCLC patients without lymph node metastasis. We retrospectively analyzed 302 patients who had undergone curative surgery for prognostic factors regarding survival and clinicopathological factors related to adjuvant chemotherapy. Nearly 90% of the patients underwent lobectomy or pneumonectomy with mediastinal lymph node resection. For the others, wedge resection were performed. The patients were diagnosed as stage IA in 35%, IB in 49% and IIA in 17%. Histopathological type (p=0.02), tumor diameter (p=0.01) and stage (p<0.001) were found to be related to adjuvant chemotherapy decisions, while operation type, lypmhovascular invasion (LVI), grade and the presence of recurrence were important factors i...
Özet Akciðer kanseri tedavisinde epidermal büyüme faktörü reseptörü (EBFR) önemli bir ilgi görmek... more Özet Akciðer kanseri tedavisinde epidermal büyüme faktörü reseptörü (EBFR) önemli bir ilgi görmektedir. Oral bir EBFR tirozin kinaz inhibitörü (EBFR-TKÝ) olan erlotinibin, birinci veya ikinci sýra kemoterapi sonrasýnda küçük hücreli dýþý akciðer kanseri (KHDAK) bulunan hastalarda saðkalýmý uzattýðý kanýtlanmýþtýr. Cilt döküntüsü erlotinib tedavisi ile iliþkili en sýk yan etkidir ve döküntünün þiddeti ile saðkalým arasýnda önemli bir korelasyon olduðu bulunmuþtur. Erlotinib tedavisi sonucu ciddi cilt döküntüsü ile beraber iyi cevap elde edilen bir akciðer adenokanseri olgusunu sunuyoruz. Anahtar Kelimeler: Akciðer tümörleri; Erlotinip; Erlotinib; Ýlaç döküntüleri; Reseptör Protein Tirozin Kinazlar. Abstract Epidermal growth factor receptor (EGFR) has received a particular attention in lung cancer treatment. Erlotinib, an orally available inhibitor of EGFR tyrosine kinase (EGFR-TKI), has been proven to prolong survival in non-small cell lung cancer (NSCLC) patients after first or seco...
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2014
PURPOSE Triple-negative breast cancers account for 15% of breast carcinomas and, when present as ... more PURPOSE Triple-negative breast cancers account for 15% of breast carcinomas and, when present as early-stage disease, they are associated with higher rates of recurrence and early distant metastasis risk when compared to hormone receptor positive and human epidermal growth factor receptor (HER-2) positive breast cancers. In this study we aimed to explore the basic clinicopathological characteristics, prognostic factors and recurrence patterns of non-metastatic triple negative breast cancer patients. METHODS In this study 561 non-metastatic triple-negative breast cancer female patients admitted to 8 different cancer centers in Turkey between 2000 and 2010 were retrospectively evaluated through their medical records, to identify the basic clinico-pathological characteristics, prognostic factors and recurrence patterns. RESULTS The ratio of triple-negative breast cancer was 12%. The median age of patients was 48 years, of whom 311 (55.4%) were premenopausal. The majority had early-stag...
Background Studies investigated different side effects of TKIs such as hypertension, dermatologic... more Background Studies investigated different side effects of TKIs such as hypertension, dermatologic side effects and hormonal changes. Thyroid hormones change is take an interest for last decade and phase 2 and 3 trial result had been analyzed retrospectively for this reason. Method A totally 246 metastatic renal cell carcinoma patients who were treated with TKI included in the study and they recruited from over 10 different oncology clinics. Results In the study 246 mRCC patients included and mean age was 60 (±8), and 183 (74%) of them were male, 63 (24%) of them were female. Following TKI therapy 15 patients (6%) became as a hyperthyroidic, 83 patients (34%) became hypothyroidic and remaining 148 patients had in normal range for TSH levels. When we subgroup the patients according to the TSH change, in 38 patients (15.4%) had THS decreasing at least 50% from baseline and 128 patients (52%) has elevated THS levels as described previous range. In survival analyses, became hyperthyro...
e14695 Background: In metastatic colorectal cancer treatment more successful results are achieved... more e14695 Background: In metastatic colorectal cancer treatment more successful results are achieved by adding anti-angiogenic therapy to the chemotherapy. Over expression of VEGF in colorectal cancer is known to be a poor prognosis factor but its effects on designating the therapy is not clear. In this study, results of the patients receiving FOLFIRI + Bevacizumab or XELOX + Bevacizumab were compared for VEGF expression. Methods: VEGF was assessed immunohistochemically in primary tumors of the 53 metastatic colorectal cancers. Severity and conformity of VEGF expression was evaluated. Results were used to assess the association with the therapy response, progression free survival (PFS) and overall survival (OS). Results: The median age of the patients was 55 (range, 32-79). In combination with bevacizumab 38 patients received FOLFIRI and 15 patients received XELOX. In 30 patients (57%) there was a strong expression of VEGF and in 23 patients (23%) the expression was weak. In the high V...
e18516 Background: Neutrophil-lymphocyte ratio (NLR) is not an only inflammation marker, but also... more e18516 Background: Neutrophil-lymphocyte ratio (NLR) is not an only inflammation marker, but also used as a prognostic index of various malignancies. Small cell lung cancer (SCLC) is considered metastatic at time of diagnosis, and survival is quite short. There is no any study evaluating the relationship between NLR and survival in SCLC. In this study, we aimed to determine the effect of NLR on overall survival. Methods: The study included 200 patients with SCLC. Survival times of patients, clinicopathological data and the results of a complete blood count at diagnosis were evaluated from patient archive files retrospectively. Patients were randomized into two groups according to NLR 5< or 5≥. Results: The median age of patients was 56 (36-80) years. One hundred and eighty one (90.5%) patients were male and 19 (9.5%) were males. Sixty-eight (34%) patients had dyspnea, 36 (18%) of cases had cough, 22 (11%) patients had back pain, and 14 (7%) of the cases had chest pain. While the ...
Asian Pacific journal of cancer prevention : APJCP, 2015
Adding taxanes to adjuvant antracycline and cyclophosphamide (AC) in combination may provide sign... more Adding taxanes to adjuvant antracycline and cyclophosphamide (AC) in combination may provide significant improvement in node-positive and high risk node-negative breast cancer (BC) patients. However, the optimal dose and the role of dose-dense (DD) chemotherapy have yet to be determined. The aim of this study was to compare the efficacy of a DD paclitaxel (P)-AC combination with conventional weekly P-AC or docetaxel D-AC combinations in patients with node-positive breast cancer. Newly diagnosed 280 node-positive BC patients diagnosed from 1998 to 2013 in three clinics were retrospectively analyzed. Demographic and medical data were collected from the medical charts. Patients were categorized to 3 groups according to treatment arms: arm A, ddAC-P; arm B, weekly P and AC combination; and arm C; T and AC combination. Adjuvant trastuzumab was added for HER2-positive patients. Kaplan-Meier survival analysis was carried out for disease free survival (DFS) and overall survival (OS). The lo...
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 1991
Twenty-one pretreatment variables were investigated for prognostic influence on survival in 301 p... more Twenty-one pretreatment variables were investigated for prognostic influence on survival in 301 previously untreated patients with ovarian carcinoma, stage IIB-IV. Patients were randomized to sequential combination chemotherapy: cyclophosphamide, doxorubicin, 5-fluorouracil, followed by cisplatin and hexamethylmelamine, or to the 3-drug combination alternating with the 2-drug combination every other month. Median overall survivals were 25 and 22 months, respectively, P greater than 0.4. Based on the results from a Cox multivariate stepwise analysis a subset of independent significant prognostic factors was found to include: residual tumor size, performance status, alkaline phosphatase, number of metastases, histological differentiation grade and type. A prognostic index was calculated for each patient and three prognostic categories of patients were determined. The 3-yr survival rates for patients with low-, intermediate-, and high-risk scores were 62, 31, and 7%, respectively. Mult...
Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth most common caus... more Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth most common cause of death (1). The therapeutic options available for the treatment of metastatic CRC have significantly increased over the past years. Together with the advances in surgical techniques, the introduction of irinotecan and oxaliplatin first and drugs targeting vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) later, have led to a median overall survival (OS) now approaching 30 months (2).
DBBHL agresif lenfomalar içinde yer alır ve en sık görülen lenfoma tipidir (%30). Germinal merkez... more DBBHL agresif lenfomalar içinde yer alır ve en sık görülen lenfoma tipidir (%30). Germinal merkezde lenfosit proliferasyonu ve dengesi apoptosis ile olmaktadır. Apoptosis ise iki yolun ortak çalısması ile düzenlenir. Bu yollardan biri hücre dısı yol digeri ise hücre içi yoldur. Hücre dısı yol çogunlukla TNF ailesi üyeleri arasında TRAIL, reseptörleri ve Fas/Fas-L üzerinden gerçeklesir. Bu ligand ve reseptör etkilesmesi sonucu hücre içi ölüm domaini (death domain; DD) aktive olur ve kaspazları aktiflestirirler. Kaspaz aktivasyonu ise apoptosis ile sonuçlanır. Bu çalısmada amacımız lenfoma patogenezinde rol oynayan reseptör ve ligandların klinik verilerle iliskisini saptamaktır. lk defa bu çalısmada literatürde daha önce yapılmamıs olan DBBHL’lı hastalarda TRAIL, TRAIL-DR4 ve TRAIL-DR5 düzeylerinin Fas/Fas-L sistemi ile birlikte tedavi öncesi ve sonrası düzeyleri ile diger klinik parametrelerin karsılastırması yapıldı. Çalısmaya Ocak 2005 ve Ekim 2007 arası DBBHL tanılı toplam 4...
e19107 Background: In this study, the efficacy and safety of pemetrexed chemotherapy was evaluate... more e19107 Background: In this study, the efficacy and safety of pemetrexed chemotherapy was evaluated retrospectively in patients who were non-responders to or who have demonstrated progression after the first and/or second line treatments in local advanced and metastatic NSCLC. Methods: 175 patients (139 males, 36 females) were assessed in years 2008 – 2012. Patients were given pemetrexed 500 mg/m2, and the ones receiving combined treatment were given pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 once in every 21 days. Supplementary steroid and vitamin treatment were administered to all patients. Age, gender, performance status (PS), stage, single agent or combined administration of treatment, progression-free survival (PFS) and overall (OS) were investigated. Patients were assessed in terms of treatment efficacy and toxicity. Results: Median follow-up period was 6 months (1 - 25), and median age was 55 years (28 - 83). In 82% of patients, PS was 0 – 1. 73% of patients were at stage 4. ...
e14705 Background: The addition of bevacizumab to chemotherapy significantly shows survival advan... more e14705 Background: The addition of bevacizumab to chemotherapy significantly shows survival advantage in metastatic colorectal cancer (mCRC), but with limited data about irinotecan combination in salvage therapy. Efficacy and toxicity of bevacizumab combination regimens were assessed in first-line and salvage therapies. Methods: Total of 1011 (659 in first-line and 352 in salvage) patients were retrospectively evaluated. Results: In first-line therapy, the ORR was 36.4%. Median PFS was 7 months for FOLFIRI, 6 months for IFL and 6 months for other chemotherapy regimens with a median overall PFS of 7 months. Median survival was 29 months for FOLFIRI, 28 months for IFL and 21 months for others with a median overall survival of 28 months. In salvage therapy, the ORR was 25.2%. Median PFS was 7 months for FOLFIRI, 7 months for IFL and 6 months for others with a median overall PFS of 7 months. Median survival was 19 months for FOLFIRI, 13 months for IFL and 21 months for others with a med...
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
Small bowel adenocarcinoma (SBA) is a rare tumor of the gastrointestinal system with poor prognos... more Small bowel adenocarcinoma (SBA) is a rare tumor of the gastrointestinal system with poor prognosis. Since these are rarely encountered tumors, there are limited numbers of studies investigating systemic treatment in advanced SBA. The purpose of this study was to evaluate the prognostic factors and systemic treatments in patients with advance SBA. Seventy-one patients from 18 Centers with advanced SBA were included in the study. Fifty-six patients received one of the four different chemotherapy regimens as first-line therapy and 15 patients were treated with best supportive care (BSC). Of the 71 patients, 42 (59%) were male and 29 (41%) female with a median age of 56 years. Median follow- up duration was 14.3 months. The median progression free survival (PFS) and overall survival (OS) were 7 and 13 months, respectively (N=71). In patients treated with FOLFOX (N=18), FOLFIRI (N=11), cisplatin-5-fluorouracil/ 5-FU (N=17) and gemcitabine alone (N=10), median PFS was 7, 8, 8 and 5 month...
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
To investigate the relationship between hepatic steatosis (HS) (at the time of diagnosis) and hep... more To investigate the relationship between hepatic steatosis (HS) (at the time of diagnosis) and hepatic metastasis (at the time of diagnosis and follow-up) in metastatic breast cancer (BC) patients by using computed tomography (CT). A total of 107 metastatic BC patients who had an abdominal CT were retrospectively enrolled in this study. Patients without HS (N=79) were regarded as the control group and those with HS constituted the HS study group (N-28). Hepatic metastases at diagnosis and during follow-up were more common in patients with HS (p=0.018 and p=0.041, respectively) and in the premenopausal group (p<0.001 and p=0.004, respectively), whereas they were similar in patients with and without HS in the postmenopausal group (p=0.655 and p=0.656, respectively). Overall survival rates were similar in patients with and without HS (p=0.606). Hepatic metastases at diagnosis and during follow-up were more frequent in patients with HS, especially in premenopausal patients. Survival w...
Asian Pacific journal of cancer prevention : APJCP, 2014
To investigate clinicopathological features in patients with recurrent colorectal cancer within 1... more To investigate clinicopathological features in patients with recurrent colorectal cancer within 1 year and more than 1 year after curative resection. We retrospectively evaluated 103 patients with disease recurrence before versus after 1 year of resection. Thirty-two patients (31%) were diagnosed with recurrence less than 1 year after curative resection for colorectal cancer (early recurrence) and 71 (69%) after more than 1 year (non-early recurrence). The early recurrence group displayed a significantly lower overall survival rate for both colon cancer (p=0, 01) and rectal cancer (p<0.001). Inadequate lymph node dissection was a significant predictor for early relapse. There were no statistically significant differences in clinicopathological variables such as age, sex, primary tumor localization, stage, depth of invasion, lymphovascular invasion and perineural invasion between the early and non-early recurrence groups. However, a K-ras mutation subgroup was significantly associ...
e20603 Background: β-glucans have antibacterial, immunomodulator and anti-cancer effects. The pre... more e20603 Background: β-glucans have antibacterial, immunomodulator and anti-cancer effects. The present study aimed to determine the effect of oral β-glucan on mucositis and leukopenia in a group of colorectal cancer patients with a high risk for neutropenia and mucositis who received adjuvant FOLFOX-4 (oxaliplatin, 5-flourouracil, and folinic acid) combination chemotherapy. Methods: This retrospective study included 62 patients with colorectal cancer that underwent a FOLFOX-4 treatment regimen between July 2009 and July 2010. Ethics committee of Erciyes University approved the study design. Colorectal cancer patients treated with a FOLFOX-4 regimen were retrospectively evaluated in 2 equal groups: One group received β-glucan (treatment group), and the other did not (control group). In both groups the level of leucocytes, neutrophils, and platelets were evaluated before and 1 week after chemotherapy. The occurrence of oral mucositis and diarrhea was noted. Data were statistically anal...
e14672 Background: There is no suggested molecular indicator in identifying which patients will b... more e14672 Background: There is no suggested molecular indicator in identifying which patients will benefit from anti-angiogenic treatment in metastatic colorectal cancer. Over expression of vascular endothelial growth factor (VEGF) and Hypoxia Inducible Factor 1-alpha (HIF-1α) are associated with bad prognosis. In this study, VEGF and HIF-1α expression and their clinical significance are studied in tumor tissues of patients with colorectal cancer receiving treatment with bevacizumab. Methods: VEGF and HIF-1α were observed immunohistochemically in primary tumors of 53 patients. The expressions were separated by evaluating low and high of VEGF and HIF-1α expression. We evaluated whether expression of VEGF and HIF-1α can help to predict treatment response, progression free survival (PFS), and overall survival (OS). Results: Fifty-three patients were enrolled in the study. Median age was 55. VEGF was strongly expressed in 30 patients (57%) whilst low expression was observed in 23 of them (...
Surgery is the only curative treatment for operable non-small lung cancer (NSCLC) and the importa... more Surgery is the only curative treatment for operable non-small lung cancer (NSCLC) and the importance of adjuvant chemotherapy for stage IB patients is unclear. Herein, we evaluated prognostic factors for survival and factors related with adjuvant treatment decisions for stage I and IIA NSCLC patients without lymph node metastasis. We retrospectively analyzed 302 patients who had undergone curative surgery for prognostic factors regarding survival and clinicopathological factors related to adjuvant chemotherapy. Nearly 90% of the patients underwent lobectomy or pneumonectomy with mediastinal lymph node resection. For the others, wedge resection were performed. The patients were diagnosed as stage IA in 35%, IB in 49% and IIA in 17%. Histopathological type (p=0.02), tumor diameter (p=0.01) and stage (p<0.001) were found to be related to adjuvant chemotherapy decisions, while operation type, lypmhovascular invasion (LVI), grade and the presence of recurrence were important factors i...
Özet Akciðer kanseri tedavisinde epidermal büyüme faktörü reseptörü (EBFR) önemli bir ilgi görmek... more Özet Akciðer kanseri tedavisinde epidermal büyüme faktörü reseptörü (EBFR) önemli bir ilgi görmektedir. Oral bir EBFR tirozin kinaz inhibitörü (EBFR-TKÝ) olan erlotinibin, birinci veya ikinci sýra kemoterapi sonrasýnda küçük hücreli dýþý akciðer kanseri (KHDAK) bulunan hastalarda saðkalýmý uzattýðý kanýtlanmýþtýr. Cilt döküntüsü erlotinib tedavisi ile iliþkili en sýk yan etkidir ve döküntünün þiddeti ile saðkalým arasýnda önemli bir korelasyon olduðu bulunmuþtur. Erlotinib tedavisi sonucu ciddi cilt döküntüsü ile beraber iyi cevap elde edilen bir akciðer adenokanseri olgusunu sunuyoruz. Anahtar Kelimeler: Akciðer tümörleri; Erlotinip; Erlotinib; Ýlaç döküntüleri; Reseptör Protein Tirozin Kinazlar. Abstract Epidermal growth factor receptor (EGFR) has received a particular attention in lung cancer treatment. Erlotinib, an orally available inhibitor of EGFR tyrosine kinase (EGFR-TKI), has been proven to prolong survival in non-small cell lung cancer (NSCLC) patients after first or seco...
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2014
PURPOSE Triple-negative breast cancers account for 15% of breast carcinomas and, when present as ... more PURPOSE Triple-negative breast cancers account for 15% of breast carcinomas and, when present as early-stage disease, they are associated with higher rates of recurrence and early distant metastasis risk when compared to hormone receptor positive and human epidermal growth factor receptor (HER-2) positive breast cancers. In this study we aimed to explore the basic clinicopathological characteristics, prognostic factors and recurrence patterns of non-metastatic triple negative breast cancer patients. METHODS In this study 561 non-metastatic triple-negative breast cancer female patients admitted to 8 different cancer centers in Turkey between 2000 and 2010 were retrospectively evaluated through their medical records, to identify the basic clinico-pathological characteristics, prognostic factors and recurrence patterns. RESULTS The ratio of triple-negative breast cancer was 12%. The median age of patients was 48 years, of whom 311 (55.4%) were premenopausal. The majority had early-stag...
Background Studies investigated different side effects of TKIs such as hypertension, dermatologic... more Background Studies investigated different side effects of TKIs such as hypertension, dermatologic side effects and hormonal changes. Thyroid hormones change is take an interest for last decade and phase 2 and 3 trial result had been analyzed retrospectively for this reason. Method A totally 246 metastatic renal cell carcinoma patients who were treated with TKI included in the study and they recruited from over 10 different oncology clinics. Results In the study 246 mRCC patients included and mean age was 60 (±8), and 183 (74%) of them were male, 63 (24%) of them were female. Following TKI therapy 15 patients (6%) became as a hyperthyroidic, 83 patients (34%) became hypothyroidic and remaining 148 patients had in normal range for TSH levels. When we subgroup the patients according to the TSH change, in 38 patients (15.4%) had THS decreasing at least 50% from baseline and 128 patients (52%) has elevated THS levels as described previous range. In survival analyses, became hyperthyro...
e14695 Background: In metastatic colorectal cancer treatment more successful results are achieved... more e14695 Background: In metastatic colorectal cancer treatment more successful results are achieved by adding anti-angiogenic therapy to the chemotherapy. Over expression of VEGF in colorectal cancer is known to be a poor prognosis factor but its effects on designating the therapy is not clear. In this study, results of the patients receiving FOLFIRI + Bevacizumab or XELOX + Bevacizumab were compared for VEGF expression. Methods: VEGF was assessed immunohistochemically in primary tumors of the 53 metastatic colorectal cancers. Severity and conformity of VEGF expression was evaluated. Results were used to assess the association with the therapy response, progression free survival (PFS) and overall survival (OS). Results: The median age of the patients was 55 (range, 32-79). In combination with bevacizumab 38 patients received FOLFIRI and 15 patients received XELOX. In 30 patients (57%) there was a strong expression of VEGF and in 23 patients (23%) the expression was weak. In the high V...
e18516 Background: Neutrophil-lymphocyte ratio (NLR) is not an only inflammation marker, but also... more e18516 Background: Neutrophil-lymphocyte ratio (NLR) is not an only inflammation marker, but also used as a prognostic index of various malignancies. Small cell lung cancer (SCLC) is considered metastatic at time of diagnosis, and survival is quite short. There is no any study evaluating the relationship between NLR and survival in SCLC. In this study, we aimed to determine the effect of NLR on overall survival. Methods: The study included 200 patients with SCLC. Survival times of patients, clinicopathological data and the results of a complete blood count at diagnosis were evaluated from patient archive files retrospectively. Patients were randomized into two groups according to NLR 5< or 5≥. Results: The median age of patients was 56 (36-80) years. One hundred and eighty one (90.5%) patients were male and 19 (9.5%) were males. Sixty-eight (34%) patients had dyspnea, 36 (18%) of cases had cough, 22 (11%) patients had back pain, and 14 (7%) of the cases had chest pain. While the ...
Asian Pacific journal of cancer prevention : APJCP, 2015
Adding taxanes to adjuvant antracycline and cyclophosphamide (AC) in combination may provide sign... more Adding taxanes to adjuvant antracycline and cyclophosphamide (AC) in combination may provide significant improvement in node-positive and high risk node-negative breast cancer (BC) patients. However, the optimal dose and the role of dose-dense (DD) chemotherapy have yet to be determined. The aim of this study was to compare the efficacy of a DD paclitaxel (P)-AC combination with conventional weekly P-AC or docetaxel D-AC combinations in patients with node-positive breast cancer. Newly diagnosed 280 node-positive BC patients diagnosed from 1998 to 2013 in three clinics were retrospectively analyzed. Demographic and medical data were collected from the medical charts. Patients were categorized to 3 groups according to treatment arms: arm A, ddAC-P; arm B, weekly P and AC combination; and arm C; T and AC combination. Adjuvant trastuzumab was added for HER2-positive patients. Kaplan-Meier survival analysis was carried out for disease free survival (DFS) and overall survival (OS). The lo...
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 1991
Twenty-one pretreatment variables were investigated for prognostic influence on survival in 301 p... more Twenty-one pretreatment variables were investigated for prognostic influence on survival in 301 previously untreated patients with ovarian carcinoma, stage IIB-IV. Patients were randomized to sequential combination chemotherapy: cyclophosphamide, doxorubicin, 5-fluorouracil, followed by cisplatin and hexamethylmelamine, or to the 3-drug combination alternating with the 2-drug combination every other month. Median overall survivals were 25 and 22 months, respectively, P greater than 0.4. Based on the results from a Cox multivariate stepwise analysis a subset of independent significant prognostic factors was found to include: residual tumor size, performance status, alkaline phosphatase, number of metastases, histological differentiation grade and type. A prognostic index was calculated for each patient and three prognostic categories of patients were determined. The 3-yr survival rates for patients with low-, intermediate-, and high-risk scores were 62, 31, and 7%, respectively. Mult...
Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth most common caus... more Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth most common cause of death (1). The therapeutic options available for the treatment of metastatic CRC have significantly increased over the past years. Together with the advances in surgical techniques, the introduction of irinotecan and oxaliplatin first and drugs targeting vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) later, have led to a median overall survival (OS) now approaching 30 months (2).
Uploads
Papers by Veli Berk